Trial reportThe Journal of investigative dermatology2020
A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S).
Trial report in The Journal of investigative dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 5 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.The Cochrane database of systematic reviews · 2025Pooled it
- A comprehensive overview of psoriatic research over the past 20 years: machine learning-based bibliometric analysis.Frontiers in immunology · 2023Pooled it
- Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review.Frontiers in immunology · 2023Pooled it
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.The Cochrane database of systematic reviews · 2022Pooled it
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.The Cochrane database of systematic reviews · 2021Pooled it
- Metabolic Complications in Autoimmune and Autoinflammatory Diseases: Pathophysiology, Clinical Implications, and Therapeutic Perspectives.Journal of clinical medicine · 2026Review
- [EJNMMI research · 2026Review
- Targeting Inflammation in Obesity and the Cardiovascular-Kidney-Metabolic Syndrome Spectrum: A Narrative Review.Obesity facts · 2026Review
- The skin as a sentinel organ for neurodegeneration: An underrecognized target for dementia prevention.Intractable & rare diseases research · 2026Review
- Phenotype-dependent effects of IL-17A inhibitors on lipid profiles in moderate-to-severe plaque psoriasis: a retrospective cohort study.Lipids in health and disease · 2026Article
- Effects of Biologic Therapies and Narrowband UVB Phototherapy on Vascular Inflammation and Systemic Inflammatory Biomarkers in Psoriasis: A Systematic Review and Narrative Synthesis of Prospective Studies.Journal of clinical medicine · 2026Review
- Cardiovascular Outcomes Associated With Biologic Therapy in Inflammatory Dermatologic Diseases: A Systematic Review.Cureus · 2026Review
- Cardiovascular Disease and Psoriasis.Dermatology and therapy · 2026Review
- From skin to heart: a state-of-the-art perspective on psoriasis-driven cardiovascular comorbidities.Frontiers in immunology · 2026Review
- Three-Dimensional Perspectives on Inflammatory Regulation in Coronary Atherosclerosis: Integrated Mechanisms of Endothelial Priming, Lipid Metabolism, and Cytokine Synergy.Reviews in cardiovascular medicine · 2026Review
- Cardiovascular Imaging in Psoriasis: A Critical Review of Current Evidence, Techniques, and Therapeutic Implications.American journal of clinical dermatology · 2026Review
- Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events.JAMA dermatology · 2025Article
- [Influence of long-term biologic therapy on metabolic biochemical parameters in moderate to severe plaque psoriasis].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2025Article
- Bridging worlds: a narrative review of IL-17 at the crossroads of inflammation and thrombosis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Review
- Cardiovascular and Kidney Outcomes After Systemic Treatment for Plaque Psoriasis: A Systematic Review and Network Meta-analysis.Dermatology and therapy · 2025Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 9 institutions in 2 countries.
Funding
Abstract
Psoriasis, a chronic immune-mediated disease, is associated with an increased risk of cardiovascular events and mortality. Secukinumab selectively neutralizes IL-17A and has reported high efficacy with a favorable safety profile in various psoriatic disease manifestations. Subsequent to the 12-week randomized, placebo-controlled, double-blind treatment period, patients with moderate-to-severe psoriasis received secukinumab for 40 weeks. Vascular inflammation using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.